| 000 | 03340nam a22003617a 4500 | ||
|---|---|---|---|
| 008 | 240807s20242024 xxu||||| |||| 00| 0 eng d | ||
| 022 | _a2168-8184 | ||
| 024 | _aPMC11144579 [pmc] | ||
| 040 | _aOvid MEDLINE(R) | ||
| 099 | _a38832202 | ||
| 245 | _aE-cigarette Use and Severe Coronavirus Disease 2019 (COVID-19) Outcomes: A Meta-Analysis. [Review] | ||
| 251 | _aCureus. 16(5):e59591, 2024 May. | ||
| 252 | _aCureus. 16(5):e59591, 2024 May. | ||
| 253 | _aCureus | ||
| 260 | _c2024 | ||
| 260 | _fFY2024 | ||
| 260 | _p2024 May | ||
| 265 | _sepublish | ||
| 265 | _tPubMed-not-MEDLINE | ||
| 266 | _d2024-08-07 | ||
| 266 | _z2024/06/04 03:44 | ||
| 520 | _aE-cigarettes have been known to cause varied poor health outcomes prior to coronavirus disease 2019 (COVID-19), but after the impact of COVID-19, evidence came out that was, in some instances, not as expected regarding the severity of COVID-19 among e-cigarette users (vapers). A meta-analysis was performed on the available evidence to comprehensively find the effect of COVID-19 on existing or past e-cigarette users (vapers). The Meta-analysis of Observational Studies in Epidemiology (MOOSE) guidelines were used to perform this meta-analysis. PubMed was searched for observational studies that described outcomes after COVID-19 positivity from December 1, 2019, to December 2023. Medical Subject Headings (MeSH) keywords were used for searching the relevant studies highlighting the relationship between COVID-19 and e-cigarette users. Calculations for pooled prevalence, 95% confidence interval (95% CI), weights for current e-cigarette users and vapers, and outcomes (events) were made. To analyze the data, Review Manager V.5.4 was used. The I2 statistic was used to assess statistical heterogeneity. The I2 statistic of >50% was considered significant heterogeneity. The "leave-one-out" method was used for sensitivity analysis. Out of 3231 studies, four studies reported data on vaping and non-vaping status and composite outcomes, resulting in a sample size of 653 COVID-19-positive cases. The pooled prevalence of being COVID-19 positive, having symptoms, or visiting an emergency room was 7.78% (653/8392). COVID-19 patients with current vaping status had decreased odds of poor outcomes compared to non-smokers, with a pooled odds ratio (OR) of 0.09 (95% CI 0.00-2.42; p>0.05) with heterogeneity between studies (I2=99%, p=0.15). Because of difficulties related to data collection and other factors, this meta-analysis was unable to conclusively establish the correlation between e-cigarette usage and severe COVID-19 outcomes such as hospitalization, admission to the intensive care unit, and fatality. Additional research using more detailed data is necessary to fully understand this correlation. Copyright © 2024, Valadez-Cuen et al. | ||
| 546 | _aEnglish | ||
| 650 | _zAutomated | ||
| 651 | _aMedStar Good Samaritan Hospital | ||
| 656 | _aHospital Medicine | ||
| 657 | _aJournal Article | ||
| 657 | _aReview | ||
| 700 |
_aShah, Viray _bMGSH |
||
| 790 | _aValadez-Cuen K, Bhatt T, Mendez IE, Solanki D, Abdi N, Shelar V, Akplor JJ, Reddy Bhumanapalli SA, Vinyak S, Patel D, Tirupathi R, Shah V, Patel UK, Rana RK | ||
| 856 |
_uhttps://dx.doi.org/10.7759/cureus.59591 _zhttps://dx.doi.org/10.7759/cureus.59591 |
||
| 942 |
_cART _dArticle |
||
| 999 |
_c14488 _d14488 |
||